Figure 2.

Splenic biopsy in a 45-year-old man with metastatic disease to the spleen from non–small cell lung cancer. (A) Staging computed tomography (CT) demonstrates a hypoattenuating lesion in the liver spleen (arrow) but no suspicion for other organ metastases. (B) T2 fat-saturated magnetic resonance imaging (MRI) demonstrates a hyperintense lesion in the spleen (arrow) that distorts the splenic contour. (C) The lesion is hypointense (arrow) on T1-weighted MRI. (D) Delayed (portal venous phase) post contrast imaging shows heterogenous enhancement of the mass (arrow). (E, F) More delayed imaging (180 seconds post contrast administration) in the axial and coronal planes demonstrates washout of the periphery of the lesion (arrow). (G) The lesion was suspicious for metastasis by imaging, and the spleen was the only site of metastatic disease. Splenic biopsy was performed under CT guidance (arrow), which confirmed the diagnosis of metastatic lung carcinoma.